Diagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says 'Walking Away' Is A Long-Term Positive
1. VCYT reported 36 cents EPS, beating expectations. Earnings beat last year's 21 cents. 2. Sales hit $118.6M, surpassing consensus and last year’s $98.2M. Revenue growth remains strong. 3. Testing revenue increased 24%, driven by Decipher and Afirma tests. Test volumes grew by over 22%. 4. Evaluating French subsidiary divestiture creates near-term operational uncertainty. Divestiture may reduce future fixed costs. 5. 2025 guidance projects testing revenue of $470-480M with margin expansion. Future growth remains robust.